[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2019001565A1 - Composición farmacéutica para prevenir o tratar el cáncer, comprendiendo el polímorfo cristalino del hexoxido tetraarsénico. - Google Patents

Composición farmacéutica para prevenir o tratar el cáncer, comprendiendo el polímorfo cristalino del hexoxido tetraarsénico.

Info

Publication number
CL2019001565A1
CL2019001565A1 CL2019001565A CL2019001565A CL2019001565A1 CL 2019001565 A1 CL2019001565 A1 CL 2019001565A1 CL 2019001565 A CL2019001565 A CL 2019001565A CL 2019001565 A CL2019001565 A CL 2019001565A CL 2019001565 A1 CL2019001565 A1 CL 2019001565A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
preventing
crystalline polymorph
treating cancer
tetraarsenic hexoxide
Prior art date
Application number
CL2019001565A
Other languages
English (en)
Inventor
Zenglin Lian
Ill Ju Bae
Original Assignee
Chemas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemas Co Ltd filed Critical Chemas Co Ltd
Publication of CL2019001565A1 publication Critical patent/CL2019001565A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/36Arsenic; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/285Arsenic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01GCOMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G28/00Compounds of arsenic
    • C01G28/005Oxides; Hydroxides; Oxyacids
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00Crystal-structural characteristics
    • C01P2002/60Compounds characterised by their crystallite size
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00Crystal-structural characteristics
    • C01P2002/70Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
    • C01P2002/72Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00Physical properties of inorganic compounds
    • C01P2006/80Compositional purity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

COMPOSICIÓN FARMACÉUTICA QUE CONTIENE HEXÓXIDO DE TETRAARSÉNICO (AS4O6) COMO INGREDIENTE ACTIVO EN UN 99% EN PESO O MÁS DEL POLIMORFO CRISTALINO A; METODO DE PREPARACION, UTIL PARA EL TRATAMIENTO DEL CANCER
CL2019001565A 2016-12-09 2019-06-07 Composición farmacéutica para prevenir o tratar el cáncer, comprendiendo el polímorfo cristalino del hexoxido tetraarsénico. CL2019001565A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020160167222A KR101844050B1 (ko) 2016-12-09 2016-12-09 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물

Publications (1)

Publication Number Publication Date
CL2019001565A1 true CL2019001565A1 (es) 2020-02-21

Family

ID=62187734

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001565A CL2019001565A1 (es) 2016-12-09 2019-06-07 Composición farmacéutica para prevenir o tratar el cáncer, comprendiendo el polímorfo cristalino del hexoxido tetraarsénico.

Country Status (16)

Country Link
US (1) US11191779B2 (es)
EP (1) EP3552611A4 (es)
JP (1) JP6824409B2 (es)
KR (1) KR101844050B1 (es)
CN (2) CN116672363A (es)
AU (1) AU2017371040B2 (es)
BR (1) BR112019010999A2 (es)
CA (1) CA3044514C (es)
CL (1) CL2019001565A1 (es)
IL (1) IL267132B (es)
MX (1) MX2019006622A (es)
MY (1) MY197417A (es)
PH (1) PH12019501292A1 (es)
SA (1) SA519401954B1 (es)
WO (1) WO2018105972A1 (es)
ZA (1) ZA201903059B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2618003T3 (es) 2012-06-13 2017-06-20 Incyte Holdings Corporation Compuestos tricíclicos sustituidos como inhibidores de FGFR
JP6449244B2 (ja) 2013-04-19 2019-01-09 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Fgfr抑制剤としての二環式複素環
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
SG10201913036RA (en) 2015-02-20 2020-02-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
PT3788047T (pt) 2018-05-04 2024-10-22 Incyte Corp Formas sólidas de um inibidor de fgfr e processos para a sua preparação
KR20210018264A (ko) 2018-05-04 2021-02-17 인사이트 코포레이션 Fgfr 억제제의 염
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR102240693B1 (ko) * 2020-05-18 2021-04-15 주식회사 케마스 육산화사비소를 포함하는 코로나바이러스 감염증의 예방 또는 치료용 약학조성물
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Fgfr阻害剤及びネクチン-4標的化剤を含む併用療法
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2309258T3 (es) 1997-10-15 2008-12-16 Polarx Biopharmaceuticals, Inc. Composiciones farmaceuticas que comprenden trioxido de arsenico para el tratamiento de linfoma no hodgkin.
WO1999024029A1 (en) 1997-11-10 1999-05-20 Memorial Sloan-Kettering Cancer Center Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
US7261906B2 (en) 1998-05-08 2007-08-28 Ill-Ju Bae Anti-cancer therapy agent of arsenic hexoxide (As4O6) of a natural chemical substance and its pharmaceutical composition
KR100272835B1 (ko) * 1998-05-08 2000-11-15 배일주 천연 화학물질 육산화사비소의 신규한 항종양 치료제로서의 용도 및 그 약학적 조성물
DE19821508C2 (de) 1998-05-13 2002-08-29 Trelleborg Automotive Tech Ct Zweikammer-Motorlager
AU2930501A (en) * 2000-01-07 2001-07-24 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
KR20020095835A (ko) 2001-06-16 2002-12-28 배일주 아폽토시스 유도제
TWI296527B (en) 2003-04-23 2008-05-11 Inst Of Nuclear Energy Res Rocaec Radioactive aesenic-containing compounds and their uses in the treatment of tumors
US8945505B2 (en) * 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
KR101572529B1 (ko) 2008-11-14 2015-11-27 배일주 암 치료를 위한 육산화사비소의 병용요법
EP3250214B1 (en) 2015-02-01 2021-09-01 Syros Pharmaceuticals, Inc. High surface-area lyophilized compositions comprising arsenic for oral administration in patients
KR101755556B1 (ko) 2016-11-18 2017-07-07 주식회사 케마스 육산화사비소의 결정다형을 포함하는 뇌암 예방 또는 치료용 약학 조성물 및 이의 제조방법
KR101834366B1 (ko) * 2016-11-21 2018-03-05 주식회사 케마스 육산화사비소의 결정다형을 포함하는 유방암 예방 또는 치료용 약학 조성물 및 이의 제조방법
KR101844049B1 (ko) 2016-12-05 2018-03-30 주식회사 케마스 육산화사비소의 결정다형을 포함하는 간암 예방 또는 치료용 약학 조성물

Also Published As

Publication number Publication date
CA3044514C (en) 2021-06-15
US11191779B2 (en) 2021-12-07
MX2019006622A (es) 2019-08-01
CA3044514A1 (en) 2018-06-14
IL267132B (en) 2022-05-01
CN116672363A (zh) 2023-09-01
CN108606979A (zh) 2018-10-02
AU2017371040B2 (en) 2020-05-07
EP3552611A4 (en) 2020-06-24
SA519401954B1 (ar) 2024-01-29
ZA201903059B (en) 2020-09-30
BR112019010999A2 (pt) 2019-10-15
PH12019501292A1 (en) 2019-12-02
EP3552611A1 (en) 2019-10-16
JP2020504088A (ja) 2020-02-06
IL267132A (en) 2019-10-31
MY197417A (en) 2023-06-16
US20200000846A1 (en) 2020-01-02
JP6824409B2 (ja) 2021-02-03
AU2017371040A1 (en) 2019-06-20
KR101844050B1 (ko) 2018-05-14
WO2018105972A1 (ko) 2018-06-14

Similar Documents

Publication Publication Date Title
CL2019001565A1 (es) Composición farmacéutica para prevenir o tratar el cáncer, comprendiendo el polímorfo cristalino del hexoxido tetraarsénico.
CL2019001369A1 (es) Composición farmacéutica para prevenir o tratar el cáncer de mama, incluido el polimorfo cristalino del hexoxido tetraarsenico y el método para producirlo.
ECSP18094790A (es) Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
DOP2017000261A (es) Derivados de ciclohexano sustituido con amido
ECSP18060342A (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos
SV2017005405A (es) Compuestos y composiciones como inhibidores de quinasa raf
CL2015003491A1 (es) Compuestos químicos.
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
DOP2019000193A (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
UY36340A (es) Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue
CR20160460A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
CL2019002986A1 (es) Nuevo compuesto sólido cristalino clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol.
CO2017007076A2 (es) Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo
CR20170269A (es) Combinaciones de compuestos activos
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
AR095032A1 (es) Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo
MX2018007517A (es) Compuestos triciclicos y composiciones como inhibidores de quinasa.
PH12016501733A1 (en) Pharmaceutical composition for preventing or treating skin rash
CO2020001506A2 (es) Nuevos compuestos
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза